 Intensive therapy small-cell lung cancer carboplatin cisplatin ifosfamide mid-cycle vincristine radiotherapy patients small-cell lung cancer patients limited-stage LS disease patients extensive-stage ES disease good performance status intensive therapy carboplatin cisplatin ifosfamide vincristine day carboplatin cycle maximum cycles weekly intervals cisplatin combination carboplatin combination Prophylactic cranial irradiation first cycle chemotherapy thoracic irradiation third cycle median nadir neutrophils /L platelets /L Chemotherapy dosages response myelosuppression treatment blood count recovery Sixty-eight percent patients cycles chemotherapy deaths treatment-related neutropenia Twenty-eight patients complete response CR assessed month end treatment patients partial response PR Median duration CR months PR months Cerebral metastases patients apparent sole site relapse CR patients median survival total group months actual survival minimum follow-up months